Effects of Blood Flow Restriction Training on Physical Function, Muscle Adaptations, and Performance in Roller Skaters

NCT07736157 | Not Yet Recruiting

• 1 other identifier: 102772026RT120
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

This randomized controlled trial evaluates the effects of adding blood flow restriction training to regular roller skating training on neuromuscular function under non-fatigued and fatigued conditions, muscle morphology, body composition, physiological responses, lower-limb strength, and roller skating performance in competitive roller skaters. Thirty participants aged 18 to 25 years will be randomly assigned to either a blood flow restriction training group or a regular training control group. Both groups will complete the same standardized 10-week roller skating training program. The blood flow restriction training group will wear pressure cuffs individualized according to each participant's arterial occlusion pressure during selected training sessions three times per week, while the control group will complete the same training without blood flow restriction. Before and after the intervention, participants will complete standardized assessments of muscle morphology using musculoskeletal ultrasound, body composition using dual-energy X-ray absorptiometry, and lower-limb strength using handheld dynamometry and one-repetition maximum tests. Physiological responses will be evaluated using blood lactate concentration and heart rate variability. Roller skating performance will be assessed using sprint, repeated-sprint, and endurance skating tests. Neuromuscular function, jump performance, and balance will also be assessed under both non-fatigued and fatigued conditions. Surface electromyography and force-platform data will be collected simultaneously during selected jump and single-leg balance tasks. The Y-Balance Test will be conducted separately without surface electromyography. The study aims to determine whether blood flow restriction training improves muscle and neuromuscular adaptations, body composition, strength, physiological responses, and roller skating performance, and whether it helps roller skaters maintain neuromuscular function, jump performance, and balance during fatigue.

Conditions

Athletic Performance Enhancement

Outcome Measures

Primary Outcomes (22)

• Change From Baseline in Ultrasound-Derived Lower-Limb Muscle Morphology

  A GE LOGIQ e portable ultrasound system will be used to assess the morphology of prespecified lower-limb muscles using standardized anatomical locations, participant positioning, transducer placement, and image-acquisition procedures. Outcomes will include muscle thickness measured in millimeters, pennation angle measured in degrees, and estimated muscle volume measured in cubic centimeters. Repeated measurements obtained during each assessment will be averaged for analysis. Changes from baseline to Week 10 will be compared between the blood flow restriction training group and the active control group.

  Baseline and Week 10 (post-intervention)

• Mean Change From Baseline in Normalized Mean RMS Amplitude During Single-Leg Countermovement Jump Without Arm Swing

  A Cometa wireless surface electromyography system (REF WP180R116PCC1) will record activity of the gluteus medius, biceps femoris, vastus medialis, vastus lateralis, medial gastrocnemius, and tibialis anterior during left- and right-leg single-leg countermovement jumps performed without arm swing. Mean root mean square amplitude will be calculated over the prespecified movement epoch and normalized to maximal voluntary contraction, expressed as a percentage of MVC. Valid trials will be averaged. Values will be reported separately by muscle, test limb, and fatigue condition; no cross-muscle or cross-limb composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol

• Mean Change From Baseline in Normalized Mean RMS Amplitude During Squat Jump With Hands on Hips

  A Cometa wireless surface electromyography system (REF WP180R116PCC1) will record activity of the gluteus medius, biceps femoris, vastus medialis, vastus lateralis, medial gastrocnemius, and tibialis anterior during the squat jump performed with the hands maintained on the hips throughout the movement. Mean root mean square amplitude will be calculated over the prespecified movement epoch and normalized to maximal voluntary contraction, expressed as a percentage of MVC. Valid trials will be averaged. Values will be reported separately for each muscle and fatigue condition; no cross-muscle composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol

• Mean Change From Baseline in Normalized Mean RMS Amplitude During Five Consecutive Countermovement Jumps

  A Cometa wireless surface electromyography system (REF WP180R116PCC1) will record activity of the gluteus medius, biceps femoris, vastus medialis, vastus lateralis, medial gastrocnemius, and tibialis anterior during five consecutive countermovement jumps. Mean root mean square amplitude will be calculated separately for each jump over the prespecified movement epoch and normalized to maximal voluntary contraction, expressed as a percentage of MVC. The five repetition-specific values will be averaged. Values will be reported separately for each muscle and fatigue condition; no cross-muscle composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol

• Mean Change From Baseline in Normalized Mean RMS Amplitude During Ten Consecutive Straight-Leg Jumps

  A Cometa wireless surface electromyography system (REF WP180R116PCC1) will record activity of the gluteus medius, biceps femoris, vastus medialis, vastus lateralis, medial gastrocnemius, and tibialis anterior during ten consecutive straight-leg jumps. Mean root mean square amplitude will be calculated separately for each jump over the prespecified movement epoch and normalized to maximal voluntary contraction, expressed as a percentage of MVC. The ten repetition-specific values will be averaged. Values will be reported separately for each muscle and fatigue condition; no cross-muscle composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol

• Mean Change From Baseline in Normalized Mean RMS Amplitude During Left- and Right-Leg Lateral Bound

  A Cometa wireless surface electromyography system (REF WP180R116PCC1) will record activity of the gluteus medius, biceps femoris, vastus medialis, vastus lateralis, medial gastrocnemius, and tibialis anterior during left- and right-leg lateral bound tasks. Mean root mean square amplitude will be calculated over the prespecified movement epoch and normalized to maximal voluntary contraction, expressed as a percentage of MVC. Valid trials will be averaged. Values will be reported separately by muscle, test limb, and fatigue condition; no cross-muscle or cross-limb composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in the Fatigue-Induced Change in Normalized Mean RMS Amplitude of the Gluteus Medius During Bilateral Countermovement Jump With Hands on Hips

  A Cometa wireless surface electromyography system (REF WP180R116PCC1) will be used to record gluteus medius activity during the bilateral countermovement jump performed with the hands maintained on the hips before and immediately after the standardized fatigue-induction protocol at baseline and Week 10. Mean root mean square amplitude will be calculated over the prespecified movement epoch and normalized to the participant's maximal voluntary contraction, expressed as a percentage of MVC. Valid trials under each fatigue condition will be averaged to obtain one value for that condition. The fatigue-induced change will be calculated as the post-fatigue value minus the pre-fatigue value. The reported outcome will be calculated as the Week 10 fatigue-induced change minus the baseline fatigue-induced change.

  Baseline and Week 10 (post-intervention), with measurements obtained before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Medial Gastrocnemius Pennation Angle at 30% of Lower-Leg Length at Rest

  A GE LOGIQ e portable ultrasound system will be used to assess medial gastrocnemius pennation angle at 30% of the distance from the midpoint of the popliteal crease to the medial malleolus, measured distally from the popliteal crease, while the participant is at rest using standardized participant positioning, transducer placement, and image-acquisition procedures. Pennation angle will be defined as the angle between a clearly visible muscle fascicle and the relevant aponeurosis according to the prespecified image-analysis protocol. Three valid images or measurements will be obtained at each assessment and averaged to produce one participant-level value. Change from baseline will be calculated as the Week 10 mean value minus the baseline mean value.

  Baseline and Week 10 (post-intervention)

• Mean Change From Baseline in Average Pennation Angle Across Seven Prespecified Lower-Limb Ultrasound Site-Condition Combinations

  A GE LOGIQ e portable ultrasound system will assess pennation angle (degrees) at seven prespecified site-condition combinations: medial gastrocnemius at 30% lower-leg length at rest and during 50% MVC isometric plantar flexion; vastus lateralis at 30%, 50%, and 70% thigh length at rest; and rectus femoris at 50% thigh length at rest and during 50% MVC isometric knee extension. Lower-leg length is the distance from the midpoint of the popliteal crease to the medial malleolus. Thigh length is measured from the greater trochanter to the lateral femoral epicondyle for the vastus lateralis and from the anterior superior iliac spine to the superior patellar border for the rectus femoris. Repeated measurements will be averaged within each combination and then across all seven combinations. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention)

• Mean Change From Baseline in Average Muscle Thickness Across Seven Prespecified Lower-Limb Ultrasound Site-Condition Combinations

  A GE LOGIQ e portable ultrasound system will assess muscle thickness (millimeters) at seven prespecified site-condition combinations: medial gastrocnemius at 30% lower-leg length at rest and during 50% MVC isometric plantar flexion; vastus lateralis at 30%, 50%, and 70% thigh length at rest; and rectus femoris at 50% thigh length at rest and during 50% MVC isometric knee extension. Lower-leg length is the distance from the midpoint of the popliteal crease to the medial malleolus. Thigh length is measured from the greater trochanter to the lateral femoral epicondyle for the vastus lateralis and from the anterior superior iliac spine to the superior patellar border for the rectus femoris. Repeated measurements will be averaged within each combination and then across all seven combinations. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention)

• Mean Change From Baseline in Average Fascicle Length Across Seven Prespecified Lower-Limb Ultrasound Site-Condition Combinations

  A GE LOGIQ e portable ultrasound system will assess muscle fascicle length (millimeters) at seven prespecified site-condition combinations: medial gastrocnemius at 30% lower-leg length at rest and during 50% MVC isometric plantar flexion; vastus lateralis at 30%, 50%, and 70% thigh length at rest; and rectus femoris at 50% thigh length at rest and during 50% MVC isometric knee extension. Lower-leg length is the distance from the midpoint of the popliteal crease to the medial malleolus. Thigh length is measured from the greater trochanter to the lateral femoral epicondyle for the vastus lateralis and from the anterior superior iliac spine to the superior patellar border for the rectus femoris. Repeated measurements will be averaged within each combination and then across all seven combinations. Change from baseline will be calculated as the Week 10 value minus the baseline value.

  Baseline and Week 10 (post-intervention)

• Mean Change From Baseline in Velocity-Derived Jump Height Across Prespecified Jump Tasks

  A force platform will assess vertical ground reaction force during bilateral CMJ and SJ with hands on hips, five consecutive CMJs and ten straight-leg jumps with hands on hips, left- and right-leg single-leg CMJs without hands on hips, and left- and right-leg lateral bounds without hands on hips. Jump height will be calculated from take-off velocity derived from the vertical force-time curve. Valid trials will be averaged within each task and fatigue condition; repeated-jump values will be averaged across repetitions. Results will be reported separately by task, limb, and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Jump-Height Decrement During Repeated Jump Tasks

  A force-platform system will be used to assess jump-height decrement during five consecutive countermovement jumps with hands on hips and ten consecutive straight-leg jumps with hands on hips. Jump height will first be calculated for each repetition from take-off velocity. Jump-height decrement will be calculated for each complete repeated-jump series using the prespecified force-platform analysis formula. One decrement value will be obtained for each repeated-jump task and fatigue condition. Results will be reported in prespecified task and fatigue-condition categories; no cross-task composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value for each category.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Maximum Relative Force Across Prespecified Jump Tasks

  A force platform will record vertical ground reaction force during bilateral CMJ and SJ with hands on hips, five consecutive CMJs and ten straight-leg jumps with hands on hips, left- and right-leg single-leg CMJs without hands on hips, and left- and right-leg lateral bounds without hands on hips. Maximum relative force will be defined as peak vertical ground reaction force divided by body weight. Valid trials will be averaged within each task and fatigue condition; repeated-jump values will be averaged across repetitions. Results will be reported separately by task, limb, and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Relative Peak Vertical Power Across Prespecified Jump Tasks

  A force platform will assess relative peak vertical power during bilateral countermovement and squat jumps, five consecutive countermovement jumps, ten consecutive straight-leg jumps, left- and right-leg single-leg countermovement jumps, and left- and right-leg lateral bounds. Instantaneous vertical power will be calculated as vertical ground reaction force multiplied by center-of-mass vertical velocity. Relative peak vertical power will be the highest instantaneous vertical power divided by body mass. Repetition-specific values from repeated-jump tasks will be averaged within each trial, and valid trials will then be averaged within each task and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Modified Reactive Strength Index Across Prespecified Jump Tasks

  A force platform will assess modified reactive strength index during bilateral CMJ and SJ with hands on hips, five consecutive CMJs and ten straight-leg jumps with hands on hips, left- and right-leg single-leg CMJs without hands on hips, and left- and right-leg lateral bounds without hands on hips. RSImod will be calculated as jump height divided by time to take-off. Valid trials will be averaged within each task and fatigue condition; repeated-jump values will be averaged across repetitions. Results will be reported separately by task, limb, and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Concentric Impulse Across Prespecified Jump Tasks

  A force platform will assess concentric impulse during bilateral CMJ and SJ with hands on hips, five consecutive CMJs and ten straight-leg jumps with hands on hips, left- and right-leg single-leg CMJs without hands on hips, and left- and right-leg lateral bounds without hands on hips. Concentric impulse will be calculated as the time integral of net vertical force during the concentric propulsion phase. Valid trials will be averaged within each task and fatigue condition; repeated-jump values will be averaged across repetitions. Results will be reported separately by task, limb, and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Maximum Landing Force Across Prespecified Jump Tasks

  A force platform will assess maximum landing force during bilateral CMJ and SJ with hands on hips, five consecutive CMJs and ten straight-leg jumps with hands on hips, left- and right-leg single-leg CMJs without hands on hips, and left- and right-leg lateral bounds without hands on hips. Maximum landing force will be defined as the highest vertical ground reaction force recorded after initial ground contact. Valid trials will be averaged within each task and fatigue condition; repeated-jump values will be averaged across repetitions. Results will be reported separately by task, limb, and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Time to Stabilization Across Prespecified Landing Tasks

  A force platform will assess time to stabilization (seconds) after landing during eight prespecified tasks: bilateral countermovement jump and squat jump with hands on hips; five consecutive countermovement jumps and ten consecutive straight-leg jumps with hands on hips; left- and right-leg single-leg countermovement jumps without hands on hips; and left- and right-leg lateral bounds without hands on hips. Time to stabilization will be defined as the interval from initial ground contact until the force signal meets the prespecified stability criterion for the required continuous duration. Valid trials will be averaged within each task and fatigue condition. For repeated-jump tasks, repetition-specific values will also be averaged. Results will be reported separately by task, limb and fatigue condition. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Total Center-of-Pressure Sway Path Length During Single-Leg Standing

  A force-platform system will be used to record center-of-pressure displacement during separate left- and right-leg single-leg standing trials. Total center-of-pressure sway path length will be calculated as the cumulative distance traveled by the center of pressure during the valid trial. Repeated valid trials will be averaged separately for each limb and fatigue condition. Results will be reported in prespecified limb and fatigue-condition categories; no cross-limb composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value for each category. Higher values indicate greater postural sway and poorer static stability.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Mean Center-of-Pressure Sway Velocity During Single-Leg Standing

  A force-platform system will be used to record center-of-pressure displacement during separate left- and right-leg single-leg standing trials. Mean center-of-pressure sway velocity will be calculated as total center-of-pressure sway path length divided by valid trial duration. Repeated valid trials will be averaged separately for each limb and fatigue condition. Results will be reported in prespecified limb and fatigue-condition categories; no cross-limb composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value for each category. Higher values indicate faster postural sway and poorer static stability.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

• Mean Change From Baseline in Center-of-Pressure Sway Envelope Area During Single-Leg Standing

  A force-platform system will be used to record center-of-pressure displacement during separate left- and right-leg single-leg standing trials. Center-of-pressure sway envelope area will be calculated as the area enclosing the center-of-pressure trajectory during the valid trial using the prespecified force-platform software algorithm. Repeated valid trials will be averaged separately for each limb and fatigue condition. Results will be reported in prespecified limb and fatigue-condition categories; no cross-limb composite will be calculated. Change from baseline will be calculated as the Week 10 value minus the corresponding baseline value for each category. Higher values indicate a larger sway range and poorer static stability.

  Baseline and Week 10 (post-intervention), assessed before and immediately after the standardized fatigue-induction protocol at each assessment

Secondary Outcomes (47)

• Change From Baseline in Force-Platform-Derived Jump and Single-Leg Balance Outcomes Under Non-Fatigued and Fatigued Conditions

  Baseline and Week 10 (post-intervention)

• Change From Baseline in Dynamic Balance Assessed by the Y-Balance Test Under Non-Fatigued and Fatigued Conditions

  Baseline and Week 10 (post-intervention)

• Change From Baseline in Body Composition and Bone Mineral Density Assessed by Dual-Energy X-Ray Absorptiometry

  Baseline and Week 10 (post-intervention)

• Change From Baseline in Lower-Limb and Trunk Maximal Isometric Strength Assessed by Handheld Dynamometry

  Baseline and Week 10 (post-intervention)

• Change From Baseline in Lower-Limb One-Repetition Maximum Strength

  Baseline and Week 10 (post-intervention)

Study Arms (2)

Blood Flow Restriction Roller Skating Training

EXPERIMENTAL

Participants will complete a 10-week standardized roller skating training program. During regular roller skating training, participants will wear blood flow restriction cuffs three times per week for 20 minutes per session. Cuff pressure will be individualized according to each participant's arterial occlusion pressure and progressively increased according to a prespecified protocol: 40% of arterial occlusion pressure during weeks 1-2, 50% during weeks 3-4, and 60% during weeks 5-10. Progression to the next pressure stage will occur only if the participant tolerates the current pressure without excessive discomfort or abnormal responses. Training attendance, heart rate, rating of perceived exertion, pressure-related discomfort, and adverse events will be monitored throughout the intervention.

Behavioral: Blood Flow Restriction Roller Skating Training

Standardized Roller Skating Training

ACTIVE COMPARATOR

Participants will complete a 10-week standardized roller skating training program with the same training content, frequency, duration, and monitoring procedures as the experimental group, but without blood flow restriction. Training attendance, heart rate, rating of perceived exertion, discomfort, and adverse events will be monitored throughout the intervention.

Behavioral: Standardized Roller Skating Training

Interventions

Blood Flow Restriction Roller Skating Training BEHAVIORAL

Participants will complete a 10-week standardized roller skating training program. During regular roller skating training, participants will wear blood flow restriction cuffs three times per week for 20 minutes per session. Cuff pressure will be individualized according to each participant's arterial occlusion pressure and progressively increased according to a prespecified protocol: 40% of arterial occlusion pressure during weeks 1-2, 50% during weeks 3-4, and 60% during weeks 5-10. Progression to the next pressure stage will occur only if the participant tolerates the current pressure without excessive discomfort or abnormal responses. Training attendance, heart rate, rating of perceived exertion, pressure-related discomfort, and adverse events will be monitored throughout the intervention.

Blood Flow Restriction Roller Skating Training

Standardized Roller Skating Training BEHAVIORAL

Participants will complete a 10-week standardized roller skating training program with the same training content, frequency, duration, and monitoring procedures as the experimental group, but without blood flow restriction. Training attendance, heart rate, rating of perceived exertion, discomfort, and adverse events will be monitored throughout the intervention.

Standardized Roller Skating Training

Eligibility Criteria

• Age: 18 Years - 25 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Aged 18 to 25 years.
• Currently active or trained competitive roller skaters with regular roller skating-specific training experience who meet at least one of the following criteria:
• Hold a Chinese National Athlete Grade II classification or higher; or
• Have completed at least 2 years of continuous roller skating-specific training, maintained systematic training during the previous year, and participated in provincial-level competitions.
• In good general health, without known cardiovascular, peripheral vascular, respiratory, neurological, metabolic, or coagulation disorders, a history of thrombosis, severe varicose veins, severe hypertension, or other conditions that may affect the safety of blood flow restriction training or high-intensity exercise testing.
• No acute or unresolved chronic injury involving the joints, muscles, ligaments, tendons, or bones of the lower limbs, and no clinically significant lower-limb pain that would interfere with roller skating, jumping, or balance testing.
• Able to safely complete roller skating-specific testing, jump and balance testing, cycle ergometer-based fatigue induction, and standardized roller skating-specific fatigue induction.
• Intact and healthy skin on the thighs, without wounds, infection, skin disease, severe allergy, or other conditions that may interfere with blood flow restriction cuff placement or surface electromyography electrode application.
• Stable sleep, training, and recovery status during the week before testing, without evidence of marked fatigue, inadequate recovery, persistent muscle soreness, substantial performance decline, severe sleep insufficiency, or serious psychological distress.
• A pain score of 0 to 3 on the Numeric Rating Scale and a pretest rating of perceived exertion of 12 or lower.
• No use during the previous week of medications, nutritional supplements, or sports supplements that may affect cardiovascular function, muscle metabolism, blood lactate, heart rate variability, neuromuscular activation, fatigue responses, or exercise performance.
• Familiar with the roller skating-specific testing procedures and able to follow all testing and training instructions.
• Willing to undergo blood flow restriction training and all required assessments.
• Able to understand the study procedures, provide written informed consent, and voluntarily participate.

You may not qualify if:

• Age outside the range of 18 to 25 years or failure to meet the required roller skating training, athlete classification, systematic training, or competition-experience criteria.
• Cardiovascular disease, peripheral vascular disease, respiratory disease, neurological disease, metabolic disease, coagulation disorder, history of thrombosis, severe varicose veins, severe hypertension, circulatory impairment, or another contraindication to blood flow restriction training or high-intensity exercise testing.
• Acute lower-limb musculoskeletal injury or an unresolved chronic injury that prevents safe completion of the testing or fatigue-induction procedures.
• Clinically significant lower-limb pain, severe sleep insufficiency, inadequate recovery, suspected overtraining, serious psychological distress, or another condition that may compromise participant safety or data validity.
• Use during the previous week of medications, nutritional supplements, or sports supplements that may affect the study outcomes.
• Skin wounds, infection, skin disease, severe allergy, or another condition affecting blood flow restriction cuff placement or surface electromyography electrode application.
• Inability to understand or comply with the study procedures or to safely complete the required surface electromyography, force-platform, Y-Balance, jump, and fatigue-induction assessments.
• Refusal to undergo blood flow restriction training or any required study procedure.
• Failure to provide written informed consent.

Sponsors & Collaborators

• Shanghai University of Sport: lead

Study Officials

• Jiwei Chen

  Shanghai University of Sport

  STUDY DIRECTOR

Central Study Contacts

Jing Wang

CONTACT

15906075548; 2521151009@sus.edu.cn

Jiwei Chen

CONTACT

15128258772; chenjiwei1997@126.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 18, 2026
• First Posted: July 30, 2026
• Study Start (Estimated): August 20, 2026
• Primary Completion (Estimated): November 30, 2026
• Study Completion (Estimated): November 30, 2026
• Last Updated: July 30, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share